This inventor holds 1 USPTO granted patent. Top assignee: Aurobindo Pharma Limited. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Innovations by Senthilkumar Natrajan
Introduction
Senthilkumar Natrajan is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of co-crystals for drug formulation. His work is characterized by a focus on enhancing the efficacy and stability of pharmaceutical compounds.
Latest Patents
Senthilkumar holds 1 patent for his invention titled "Process for the preparation of DL-proline co-crystal of Dapagliflozin." This patent describes a novel process for creating a co-crystal of Dapagliflozin with DL-Proline, which is essential for the preparation and purification of Dapagliflozin. The invention also outlines a method for producing Dapagliflozin (R,S)-1,2-propanediol monohydrate, showcasing his innovative approach to pharmaceutical development.
Career Highlights
Senthilkumar is currently employed at Aurobindo Pharma Limited, a leading pharmaceutical company known for its commitment to quality and innovation. His role at Aurobindo Pharma allows him to apply his expertise in drug formulation and development, contributing to the company's mission of providing affordable and effective medications.
Collaborations
Throughout his career, Senthilkumar has collaborated with talented professionals in the industry, including Vittal Tangirala and Sivakumaran Meenakshisunderam. These collaborations have fostered a creative environment that encourages the exchange of ideas and advancements in pharmaceutical research.
Conclusion
Senthilkumar Natrajan's contributions to the field of pharmaceuticals through his innovative patent and work at Aurobindo Pharma Limited highlight his dedication to improving drug formulation processes. His efforts continue to impact the industry positively, paving the way for future advancements in pharmaceutical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
